Actavis is a global specialty pharmaceutical company, with products addressing diseases in the central nervous system, gastroenterology and women’s health. Auden Mckenzie is a company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the United Kingdom. The acquisition will make Actavis the number one supplier of generic pharmaceuticals in the U.K.
This is the second acquisition announcement by Actavis in the last three months. The company said it would acquire Allergan, a Botox maker, for $66 billion in November.
More articles on GI/endoscopy:
Atlanta Gastroenterology Associates adds 4 physicians
enGene raises $11.5M for intestinal gene delivery platform development
Fujifilm’s ground breaking technology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.